3B Blackbio Dx (532067) Stock Overview
Engages in the design, development, manufacturing, and commercialization of molecular diagnostic solutions for infectious diseases, oncology, human genetics and antimicrobial resistance in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
532067 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
3B Blackbio Dx Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,624.90 |
| 52 Week High | ₹2,100.00 |
| 52 Week Low | ₹1,151.00 |
| Beta | 0.30 |
| 1 Month Change | 14.38% |
| 3 Month Change | 16.88% |
| 1 Year Change | -14.32% |
| 3 Year Change | 290.46% |
| 5 Year Change | 419.80% |
| Change since IPO | 9,629.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 532067 | IN Chemicals | IN Market | |
|---|---|---|---|
| 7D | 1.8% | -5.1% | -3.1% |
| 1Y | -14.3% | -1.9% | 2.6% |
Return vs Industry: 532067 underperformed the Indian Chemicals industry which returned -2.1% over the past year.
Return vs Market: 532067 underperformed the Indian Market which returned 2.5% over the past year.
Price Volatility
| 532067 volatility | |
|---|---|
| 532067 Average Weekly Movement | 7.1% |
| Chemicals Industry Average Movement | 5.0% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in IN Market | 8.5% |
| 10% least volatile stocks in IN Market | 3.2% |
Stable Share Price: 532067's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 532067's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | 85 | Dhirendra Dubey | 3bblackbio.com |
3B Blackbio Dx Limited engages in the design, development, manufacturing, and commercialization of molecular diagnostic solutions for infectious diseases, oncology, human genetics and antimicrobial resistance in India. The company offers qPCR-based and lateral flow assays rapid tests and Next Gen Sequencing -based molecular diagnostic kits for accurate and reliable testing on patient samples under the TRUPCR, TRUNGS, TRURAPID, brand for testing on patient samples to diagnostics labs. It also offers agrochemical products; technical support and training services.
3B Blackbio Dx Limited Fundamentals Summary
| 532067 fundamental statistics | |
|---|---|
| Market cap | ₹13.92b |
| Earnings (TTM) | ₹492.17m |
| Revenue (TTM) | ₹1.04b |
Is 532067 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 532067 income statement (TTM) | |
|---|---|
| Revenue | ₹1.04b |
| Cost of Revenue | ₹285.66m |
| Gross Profit | ₹754.58m |
| Other Expenses | ₹262.41m |
| Earnings | ₹492.17m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 57.44 |
| Gross Margin | 72.54% |
| Net Profit Margin | 47.31% |
| Debt/Equity Ratio | 0.09% |
How did 532067 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/21 04:35 |
| End of Day Share Price | 2026/01/21 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
3B Blackbio Dx Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.